Skip to main content

Biotech startup inks $30M deal to fuel China expansion

MediBeacon Inc., a St. Louis-based biotech developer, has reached a $30 million deal giving China's Huadong Medicine Co. Ltd. exclusive rights to MediBeacon's portfolio in China, Hong Kong, Macau and Taiwan.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.